Wealth in Singapore Market Analysis and Growth Forecast by Regions, Type and Application to 2023

Singapore is Asia’s pre-eminent offshore investment center, with 80% of the wealth invested in funds sourced from non-residents in 2015. However, the onshore market is a major source of assets under management (AUM) in its own right, with 1.2 million affluent individuals in 2016 despite the city state’s small population. An onshore operation is clearly worth the effort for any wealth manager targeting mass affluent investors.

Specifically the report -
* Sizes the affluent market (both by number of individuals and the value of their liquid assets) using our proprietary datasets.
* Analyzes which asset classes are favored by Singaporean investors and how their preferences impact the growth of the total savings and investments market.
* Examines HNW clients’ attitudes towards non-traditional investments, such as property and commodities.
* Identifies key drivers and booking centers for offshore investments.
* Examines the tax landscape in Singapore and future implications for investors.

Browse Detail Report With TOC @
http://www.hexareports.com/report/wealth-in-singapore-sizing-the-market-opportunity-2017

Scope
* HNW individuals totaled 29,660 in 2016 – little changed from 2015, a tiny proportion of the overall population, and well below the levels seen in other wealth hubs such as the US and Switzerland.
* HNW liquid assets growth will slow to 7.0% a year between 2015 and 2020.
* Bonds will be the fastest-growing asset class, but more due to greater availability than client demand.
* While Singapore attracts significant offshore investment, HNW residents are also keen to invest abroad, with almost half of AUM invested offshore.

Request A Sample copy of This Report @
http://www.hexareports.com/report/wealth-in-singapore-sizing-the-market-opportunity-2017/request-sample

Reasons To Buy
1. Benchmark your share of the Singaporean wealth market against the current market size.
2. Forecast your future growth prospects using our projections for the market to 2020.
3. Identify your most promising client segment by analyzing penetration of affluent individuals in Singapore.
4. Evaluate your HNW proposition by understanding how the Singaporean tax system impacts HNW clients.
5. Review your offshore strategy by identifying HNW motivations for offshore investments and their preferred booking centers.

Browse More Financial Services Related Market Research Reports:

• Banking as a Marketplace: Opportunities and Threats -
http://www.hexareports.com/report/banking-as-a-marketplace-opportunities-and-threats

• Consumer Payments Country Snapshot: Canada 2016 -
http://www.hexareports.com/report/consumer-payments-country-snapshot-canada-2016

• Advisory Asset Management: HNW Demand and Drivers -
http://www.hexareports.com/report/advisory-asset-management-hnw-demand-and-drivers

Aesthetic Lasers and Energy Devices Market Study by Price, Revenue and Gross Margin Analysis with its important Types and Application to 2023

The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments – Minimally Invasive Body Contouring Devices, Non Invasive Body Contouring Devices and Laser Resurfacing Devices.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Browse Detail Report With TOC @
http://www.hexareports.com/report/italy-aesthetic-lasers-and-energy-devices-market-outlook-to-2023

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
* Market size and company share data for Aesthetic Lasers and Energy Devices market segments – Minimally Invasive Body Contouring Devices, Non Invasive Body Contouring Devices and Laser Resurfacing Devices.
* Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
* 2016 company shares and distribution shares data for each of the market segments.
* Global corporate-level profiles of key companies operating within the Italy Aesthetic Lasers and Energy Devices market.
* Key players covered include Cynosure, Inc., Syneron Medical Ltd, Valeant Pharmaceuticals International Inc and Others.

Request A Sample copy of This Report @
http://www.hexareports.com/report/italy-aesthetic-lasers-and-energy-devices-market-outlook-to-2023/request-sample

Reasons To Buy
1. Develop business strategies by identifying the key market segments poised for strong growth in the future.
2. Develop market-entry and market expansion strategies.
3. Design competition strategies by identifying who-stands-where in the market.
4. Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
5. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Browse More Medical Devices Related Market Research Reports:

• Russia Aesthetic Lasers and Energy Devices Market Outlook to 2023 -
http://www.hexareports.com/report/russia-aesthetic-lasers-and-energy-devices-market-outlook-to-2023

• Russia Surgical Generators Market Outlook to 2023 -
http://www.hexareports.com/report/russia-surgical-generators-market-outlook-to-2023

• Russia Ureteroscopes Market Outlook to 2023 -
http://www.hexareports.com/report/russia-ureteroscopes-market-outlook-to-2023

Ureteroscopes Market Growth Forecast, Demand and Development Research Report to 2023

The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments – Non-Video Ureteroscopes and Flexible Video Ureteroscopes.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Browse Detail Report With TOC @
http://www.hexareports.com/report/germany-ureteroscopes-market-outlook-to-2023

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
* Market size and company share data for Ureteroscopes market segments – Non-Video Ureteroscopes and Flexible Video Ureteroscopes.
* Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
* 2016 company shares and distribution shares data for each of the market segments.
* Global corporate-level profiles of key companies operating within the Germany Ureteroscopes market.
* Key players covered include Olympus Corporation, KARL STORZ GmbH & Co KG and Others.

Request A Sample copy of This Report @
http://www.hexareports.com/report/germany-ureteroscopes-market-outlook-to-2023/request-sample

Reasons To Buy
1. Develop business strategies by identifying the key market segments poised for strong growth in the future.
2. Develop market-entry and market expansion strategies.
3. Design competition strategies by identifying who-stands-where in the market.
4. Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
5. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Browse More Medical Devices Related Market Research Reports:

• Italy Ureteroscopes Market Outlook to 2023 -
http://www.hexareports.com/report/italy-ureteroscopes-market-outlook-to-2023

• Spain Aesthetic Lasers and Energy Devices Market Outlook to 2023 -
http://www.hexareports.com/report/spain-aesthetic-lasers-and-energy-devices-market-outlook-to-2023

• Spain Surgical Generators Market Outlook to 2023 -
http://www.hexareports.com/report/spain-surgical-generators-market-outlook-to-2023

Surgical Generators Market Report Research Analysis, Growth Opportunities and Recent Trends by Leading Regions, Types and Application from 2017 to 2023

The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) within market segments – Argon Plasma Coagulation Generators, Electrosurgical RF Generators, Electrocautery Generators and Ultrasonic Generators.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Browse Detail Report With TOC @

http://www.hexareports.com/report/germany-surgical-generators-market-outlook-to-2023

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope
* Market size and company share data for Surgical Generators market segments – Argon Plasma Coagulation Generators, Electrosurgical RF Generators, Electrocautery Generators and Ultrasonic Generators.
* Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.
* 2016 company shares and distribution shares data for each of the market segments.
* Global corporate-level profiles of key companies operating within the Germany Surgical Generators market.
* Key players covered include Olympus Corporation, Medtronic plc, ERBE Elektromedizin GmbH and Others.

Request A Sample copy of This Report @
http://www.hexareports.com/report/germany-surgical-generators-market-outlook-to-2023/request-sample

Reasons To Buy
1. Develop business strategies by identifying the key market segments poised for strong growth in the future.
2. Develop market-entry and market expansion strategies.
3. Design competition strategies by identifying who-stands-where in the market.
4. Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
5. What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Browse More Medical Devices Related Market Research Reports:

• Germany Ureteroscopes Market Outlook to 2023 -
http://www.hexareports.com/report/germany-ureteroscopes-market-outlook-to-2023

• Italy Aesthetic Lasers and Energy Devices Market Outlook to 2023 -
http://www.hexareports.com/report/italy-aesthetic-lasers-and-energy-devices-market-outlook-to-2023

• Italy Surgical Generators Market Outlook to 2023 -
http://www.hexareports.com/report/italy-surgical-generators-market-outlook-to-2023

Osteoporosis Therapeutics Market Research Size, Share, Trends Analysis and Growth Forecast by Regions, Type and Application to 2022

Osteoporosis, the most common metabolic bone disease, is characterized by low bone mass, microarchitectural deterioration of bone tissue, and a consequent increase in fracture risk. Osteoporosis is generally known as an asymptomatic disease, as there are no visible signs until a fracture occur. In most of the cases, fracture is the clinical outcome associated with osteoporosis, and it has a complex pathogenesis that involves trauma to the bone and increased skeletal fragility.

Osteoporosis is a major global public health problem, associated with significant morbidity, mortality, and socioeconomic burden. An aging global population will result in an increased number of people living with the condition, thereby acting as a driver for revenue growth.

The osteoporosis market is undergoing a gradual transition from a focus on antiresorptive therapies to anabolic drug treatment. The market is set to be driven by recently launched products, and the approval of drugs that will supplement current market leaders and offer greater therapeutic options.

Browse Detail Report With TOC @
http://www.hexareports.com/report/osteoporosis-therapeutics-in-asia-pacific-markets-to-2022

The marketed products landscape comprises a wide range of treatment options, including bisphosphonates, SERMs, RANKL inhibitors, a dual-action non-bisphosphonate (strontium ranelate), calcitonins and PTH analogues. Nevertheless, significant unmet need remains for products that can improve bone formation, as well as effective antiresorptive therapies that offer increased compliance with few side effects.

Scope
* The osteoporosis Asia-Pacific market will be valued at $7.7 billion in 2022, growing from $4.5 billion in 2015 at a CAGR of 7.8%.
o Bisphosphonates and SERMs dominate the osteoporosis market. However, unmet needs exist in terms of safety and efficacy. Will the drugs under development fulfill the unmet needs of the osteoporosis market?
o How will immunotherapies such as Prolia contribute to growth?
o What effect will the patent expirations of currently branded therapies have on market value?
* The pipeline contains a range of molecule types and molecular targets, including those that are well established in osteoporosis, and novel, first-in-class therapies.
o Which molecular targets appear most frequently in the pipeline?
o Is there strong potential for the pipeline to address unmet needs within the osteoporosis market?
o Will the pipeline address unmet needs related to limited anabolic therapies for osteoporosis patients?

Request A Sample copy of This Report @
http://www.hexareports.com/report/osteoporosis-therapeutics-in-asia-pacific-markets-to-2022/request-sample

Reasons to buy
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
2. Visualize the composition of the osteoporosis market in terms of dominant therapies, with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
3. Analyze the osteoporosis pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
4. Understand the potential of late-stage therapies, with extensive profiles of products that could enter the market over the forecast period, highlighting clinical performance, potential commercial positioning, – and how they will compete with other therapies.
5. Predict osteoporosis market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.
6. Identify commercial opportunities in the osteoporosis deals landscape by analyzing trends in licensing and co-development deals.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017

• Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017

• Colorectal Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/colorectal-cancer-heat-map-and-analysis

Non-Small Cell Lung Cancer Therapeutics Market Growth Analysis, Trends Forecast by Regions, Type and Application to 2022

Non-Small Cell Lung Cancer (NSCLC) is the most common cancer and cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012 globally, accounting for 13% of the total number of cancer cases. Over half of the incident cases of NSCLC are diagnosed in patients over the age of 65 – a high-risk age range for lung cancer. As the aged population is projected to increase, the prevalence of lung cancer is anticipated to increase, thereby acting as a driver for revenue growth. The poor prognosis, particularly for patients with advanced disease, has created a pressing need for improved therapeutic options. The NSCLC market is undergoing a gradual change from a focus on generic chemotherapy regimens to a complex treatment landscape based on different NSCLC subtypes.

In the current market, patients with non-squamous histology can be treated with more efficacious therapies such as Alimta (pemetrexed), while patients harboring activating mutations in EGFR or ALK can be prescribed targeted therapies such as Tarceva, Iressa, Xalkori and Gilotrif. Opdivo (nivolumab) – a mAb immune checkpoint inhibitor targeted towards Programmed cell Death (PD) 1 – is a recent market entrant, gaining approval for treating advanced.

Browse Detail Report With TOC @
http://www.hexareports.com/report/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-to-2022

While the NSCLC developmental pipeline must aim to improve the outlook for all patients, there is currently a lack of options for patients with squamous cell histology or other detectable molecular characteristics besides EFGR and ALK mutations. Therapies that target mutant T790M and KRAS are being developed in the pipeline, with osimertinib, targeting T790M, gaining approval in Japan in 2016.

Scope
* The NSCLC Asia-Pacific market will be valued at $4.9 billion in 2022, growing from $2.7 billion in 2015 at a CAGR of 8.7%.
o How will immunotherapies such as Keytruda contribute to the growth?
o What effect will patent expirations of currently branded therapies have on market value?
* The NSCLC pipeline is large and diverse, with an increased presence of mAbs and targeted therapies.
o What are the common targets and mechanisms of action of pipeline therapies?
o Will the pipeline address unmet needs such as a lack of treatments for squamous cell patients?
o What implications will the increased focus on targeted therapies have on the future of NSCLC treatment?
* Numerous late-stage pipeline therapies with a strong clinical record have the potential to enter the market over the forecast period.
o How have the late-stage therapies performed in clinical trials?
o How would the approval of rociletinib to treat T790M mutant patients affect the competitive
* landscape, with its competitor osimertinib (AZD-9291) already approved in Japan in 2016?
o How would the approval of abemaciclib to treat KRAS mutant patients affect the competitive
o landscape, with no targeted therapy currently available to address this patient subset?

Request A Sample copy of This Report @
http://www.hexareports.com/report/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-to-2022/request-sample

Reasons to buy
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis, including a clinical comparison of marketed therapies.
2. Visualize the composition of the NSCLC market in terms of dominant therapies for each patient subset along with their clinical and commercial standing. Unmet needs are highlighted to allow a competitive understanding of gaps in the current market.
3. Analyze the NSCLC pipeline and stratify pipeline therapies by stage of development, molecule type and molecular target.
4. Understand the potential of late-stage therapies with extensive profiles of products that could enter the market over the forecast, highlighting clinical performance, potential commercial positioning, and how they will compete with other therapies.
5. Predict NSCLC market growth in the five Asia-Pacific markets with epidemiological and annual cost of therapy forecasts across India, China, Australia, South Korea and Japan, as well as individual contributions of promising late-stage molecules to market growth.

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Type 1 Diabetes Mellitus – Heat Map and Analysis -
http://www.hexareports.com/report/type-1-diabetes-mellitus-heat-map-and-analysis

• Prostate Cancer – Heat Map and Analysis -
http://www.hexareports.com/report/prostate-cancer-heat-map-and-analysis

• Type 2 Diabetes Mellitus – Heat Map and Analysis -
http://www.hexareports.com/report/type-2-diabetes-mellitus-heat-map-and-analysis

Urological Cancer Market Segmentation and Analysis by Recent Trends, Development and Growth by Regions to 2022

Urological cancers are thought to account for 19.5% of global cancer prevalence, with kidney, prostate, testicular and bladder cancer – the key indications covered in this report – accounting for the majority of that figure. Urological cancers affect the male and female urinary tract and the male reproductive organs. Prostate cancer is the most prevalent of these malignancies.

A number of common etiologic factors have been strongly characterized as raising the risk of developing urological cancers, including age, chronic inflammation, gender, obesity, tobacco usage and heritable cancer syndromes. The risk of cancer increases greatly in patients over the age of 65. Populations in developed countries are projected to become increasingly aged and show rising obesity incidence, which will drive both cancer prevalence and revenue growth for its treatments.

Hormone therapies for prostate cancers and angiogenesis inhibitors for renal cell carcinoma are currently the most commercially successful urological cancer drugs. However, there has been a shift towards the clinical testing of cancer immunotherapies – such as Opdivo, which was recently approved for renal cell carcinoma.

Browse Detail Report With TOC @
http://www.hexareports.com/report/global-urological-cancer-market
The forecast period will also witness the approval of a greater number of targeted therapies, which by their nature have less toxicity associated with their use, and as a result can be administered to patients with poor performance statuses, therefore increasing the overall survival of this group and the number of treatment cycles they may receive.

Scope
* Global revenues for the urological cancer market are forecast to grow at a Compound Annual Growth Rate (CAGR) of 10.39%, from $17.9 billion in 2015 to $35.9 billion in 2022. Which drugs will achieve blockbuster status and how will the key player companies perform during the forecast period?
* The urologic oncology pipeline is large and diverse, and contains 817 products. How does the composition of the pipeline compare with that of the existing market?
* What mechanisms of action and molecule types are most common for pipeline drugs being trialed in the various key indications?
* How will the market shares and CAGRs of the top 20 companies compare within this therapy area?
* What proportion of the key players’ revenues will be attributable to urological cancers?

Request A Sample copy of This Report @
http://www.hexareports.com/report/global-urological-cancer-market/request-sample

Reasons to buy
1. Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options available at each stage of diagnosis
2. Visualize the composition of the urological cancer market across each indication, in terms of dominant molecule types and targets, highlighting the key commercial assets and players
3. Analyze the urological cancer pipeline and stratify by stage of development, molecule type and molecular target, with a granular breakdown across key indications
4. Understand the growth in patient epidemiology and market revenues for the urological cancer market globally and across the key players and product types
5. Stratify the market in terms of the split between generic and premium products, and assess the role of these product types in the treatment of the various urological cancers
6. Identify commercial opportunities in the urological cancer deals landscape by analyzing trends in licensing and co-development deals

Browse More Pharmaceuticals & Healthcare Related Market Research Reports:

• Antibacterial Therapies Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/antibacterial-therapies-drug-development-pipeline-review-2017

• Cardiovascular Disorders Drug Development Pipeline Review, 2017 -
http://www.hexareports.com/report/cardiovascular-disorders-drug-development-pipeline-review-2017

• Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 -
http://www.hexareports.com/report/non-small-cell-lung-cancer-therapeutics-in-asia-pacific-markets-to-2023